Skip to main content

Table 1 In vivo efficacy of DOX-SLN and free doxycycline against B. melitensis in acute phase

From: Doxycycline-encapsulated solid lipid nanoparticles for the enhanced antibacterial potential to treat the chronic brucellosis and preventing its relapse: in vivo study

TreatmentAcute stage
CFUs (Log10) in spleenLog CFUs reductionCFUs (Log10) in liverLog CFUs reduction
Untreated5.03 ± 0.030.005.05 ± 0.050.00
Free SLN5.02 ± 0.080.015.04 ± 0.010.01
DOX-SLN4.295 ± 0.270.73*4.30 ± 0.310.75*
Free doxycycline4.301 ± 0.320.72*4.31 ± 0.910.74*
  1. Comparisons were performed between all treatments and control without treatment: * P < 0.05